Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Reversibility of Rocuronium After Neostigmine
NCT00001520Phase 4Completed
- Sponsor
- National Institutes of Health
- Start
- Sep 1996
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of neostigmine in neuromuscular blockade (NMB), sponsored by National Institutes of Health. Primary endpoint: Dose of neostigmine necessary for early reversal. Started Sep 1996; status: completed.
02
Drugs
neostigmine
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT00001520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001520.